Arrowhead Pharmaceuticals/$ARWR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.

Ticker

$ARWR
Primary listing

Industry

Biotechnology

Employees

609

ISIN

US04280A1007

ARWR Metrics

BasicAdvanced
$2.2B
-
-$1.14
0.90
-

What the Analysts think about ARWR

Analyst ratings (Buy, Hold, Sell) for Arrowhead Pharmaceuticals stock.

Bulls say / Bears say

Arrowhead Pharmaceuticals' most advanced candidate, plozasiran, has completed a Phase 3 study in patients with familial chylomicronemia syndrome (FCS) and is expected to launch commercially in 2025, pending FDA approval. (TradingView News)
The company has a robust pipeline of 16 clinical-stage investigational medicines ranging from Phase 1 to Phase 3, indicating strong potential for future growth. (TradingView News)
Analysts have maintained a 'Moderate Buy' consensus rating for Arrowhead Pharmaceuticals, with an average price target of $40.70, suggesting potential upside from current levels. (MarketBeat)
Arrowhead Pharmaceuticals reported a net loss of $599.5 million in 2023, a significant increase from $205.3 million in 2022, primarily due to decreased revenue from license and collaboration agreements and increased R&D expenses. (TradingView News)
Sanford C. Bernstein reduced its price target for Arrowhead Pharmaceuticals from $27.00 to $24.00, indicating a more cautious outlook on the stock's performance. (MarketBeat)
The company's heavy reliance on clinical-stage product candidates means that any delays or failures in clinical trials could materially harm its business and stock performance. (TradingView News)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.

ARWR Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ARWR Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ARWR

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs